All AbMole products are for research use only, cannot be used for human consumption.
Ribociclib (LEE011) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is 1000 times less active against cyclin B/CDK1 complex.
 |
Source | Bio Pharma (2018). Figure 5. LEE011 |
| Method | qRT-PCR | |
| Cell Lines | MDCKII-ABCB1, MDCKII-ABCG2, or MDCKII-parent cells | |
| Concentrations | 12 and 20 μM | |
| Incubation Time | 72 h | |
| Results | The ABCB1 and ABCG2 expression rate was assessed using the ΔΔCt method, and we observed no significant change in the transporter-encoding gene studied, as demonstrated in Figure 5D. |
| Cell Experiment | |
|---|---|
| Cell lines | MYCN amplified neuroblastoma cell lines |
| Preparation method | Pharmacologic growth inhibition LEE011 was provided by Novartis pharmaceuticals. A panel of neuroblastoma cell lines, selected based upon prior demonstration of substrate adherent growth, was plated in triplicate on the Xcelligence Real-Time Cell Electronic Sensing system (ACEA Biosciences) and treated 24 hours later with a four-log dose range of inhibitor or with a DMSO control. Cell indexes were monitored continuously for ~100 hours, and IC50 values were determined as follows: Growth curves were generated by plotting the cell index as a function of time and were normalized to the cell index at the time of treatment for a baseline cell index of 1. The area under the normalized growth curve from the time of treatment to 96 hours post-treatment was then calculated using a baseline area of 1 (the cell index at the time of treatment). Areas were normalized to the DMSO control, and the resulting data were analyzed using a non-linear log inhibitor vs. normalized response function (Graphpad). All experiments were repeated at least once. |
| Concentrations | 0~10µM |
| Incubation time | 96h |
| Animal Experiment | |
|---|---|
| Animal models | BE2C, NB-1643, or EBC1 cell line-derived xenografts of CB17 SCID−/− mice |
| Formulation | 0.5 % methylcellulose |
| Dosages | 200 mg/kg |
| Administration | oral |
| Molecular Weight | 434.54 |
| Formula | C23H30N8O |
| CAS Number | 1211441-98-3 |
| Solubility (25°C) | DMSO 10 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related CDK Products |
|---|
| (E/Z)-Zotiraciclib citrate
(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor. |
| Abemaciclib metabolites M2
Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively. |
| CDK9-IN-1
CDK9-IN-1 is a novel, selective CDK9 inhibitor, with an IC50 of 39 nM for CDK9/CycT1, it can be used for the research of HIV infection. |
| XO44
XO44 (PF-6808472) is a broad-spectrum covalent kinase probe. |
| ML 315
ML 315 is a selective dual inhibitor of CDK and DYRK with IC50s of 68 nM and 282 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
